Patent Application
20080318869
The invention relates to the field of wound healing. In particular, it relates to treatment of wounds inflicted by disease, surgery, injury, etc. More particularly it relates to treatment of wounds in irradiated individuals.
Combined radiation and wound injury occurs after severe nuclear accidents that accompany explosions or nuclear attacks. High doses of ionizing radiation can cause bone marrow aplasia and delay wound healing. Shi et al. Radiat Res. 2004 Jul;162(l):56-63.
The wound healing process is adversely effected by irradiation. Irradiation causes a delay in the overall process. The early phase inflammatory response is inhibited. The formation and maturation of granulation tissue is retarded. And the reepithelialization process is delayed. These result in an overall prolongation of healing time Gu et al., J Environ Pathol Toxicol Oncol. 1998; 17:117-23. Particular components of the wound healing process that are affected include infiltrating macrophages and neutrophils, blood vessels, fibroblasts, collagen synthesis and secretion. Ibid.
There is a continuing need in the art for remedies and tools to help ameliorate the after-effects of nuclear accidents or attacks. There is a continuing need in the art for remedies and tools to help ameliorate the side-effects of therapeutic radiation.
According to the present invention a method is provided for stimulating wound healing in a radiation-exposed mammal. An effective amount of Substance P or an analog thereof is administered to a mammal that has been exposed to radiation and that has a wound. The analog is selected from the group consisting of [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8 ]-substance P, [p-Cl-Phe7,8]-substance P, [Sar9,Met (O2)11]-substance P, and analogs having the amino acid backbone RPKPQQFFGLM-NH2. Healing of the wound is stimulated.
Animals with wounds that have been irradiated do not heal as well as non-irradiated animals. It is a discovery of the present invention that substance P or its bioactive analogs can ameliorate the negative effects of irradiation on -the wound healing process.
Substance P (RPKPQQFFGLM-NH2; SEQ ID NO: 1) or a bioactive analog thereof such as Sar9,Met(O2)11-Substance P can be administered to stimulate wound healing. The bioactive analog can be selected from the group consisting of [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8]-substance P, Sar9, Met(O2)11-Substance P, and [p-Cl-Phe7,8]-substance P. Other compounds which function in the same way can be identified by their ability to compete with substance P for binding to its receptor (NK-1) or for their ability to agonize the NK-1 receptor. Compounds which have the same amino acid backbone as substance P can be routinely modified and tested for receptor agonist activity. Routine assays for such activities are known in the art and can be used.
The substance P or analog can be administered by any method known in the art, including via aerosol inhalation. Intravenous, topical, intratracheal, intrabronchial, intramuscular, sublingual, and oral administrations can also be used. Suitable dosages include 0.05 to 5 nanomolar substance P or analog for administration, or 0.1 to 2 nanomolar, or 0.5 to 1.5 nanomolar. For aerosol administration dosages include 0.05 to 5 micromolar substance P or analog, preferably 0.1 to 2 micromolar, and more preferably 0.5 to 1.5 micromolar. For direct intramuscular injection a 2 micromolar solution can be used, for example. Other useful concentration ranges of substance P or its bioactive analog in an aerosol administered is between 0.001 and 75 μM. It can be advantageously administered as a liquid at a concentration between about 0.1 and 10 μM. Concentrations for topical administration are in the range of 1μM to 50 μM . Amounts to be administered are typically between 1 μM and 10 μM.
Wounds which are amenable to treatment according to the present invention are those on the surface as well as internal to an animal body. The wounds may be caused by accident, disease, or purposefully. The wounds can, for example, be surgical wounds. Amenable wounds include but are not limited to cutaneous wounds, muscular wounds, osseus lesions, gastrointestinal anastamoses, decubitus ulcers, gastrointestinal ulcers, and burn wounds. The methods of the present invention can be applied to any mammal, including humans, horses, sheep, primates such as monkeys, apes, gibbons, chimpanzees, rodents such as mice, rats, guinea pigs, hamsters, ungulates such as cows.
While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.
The male mice fought while confined with four mice/bin. They sustained extensive tail wounds from biting. We then exposed the mice to either 7, 8, or 9 Gy 60 Cobalt gamma radiation in a single acute dose. [Sar9,Met(02)11]-substance P was administered by direct muscle injection in a 0.5 ml bolus at 2 micromolar concentration. Control animals received injections of normal saline. At 7 weeks post-radiation exposure, the control mice had unhealed tail wounds (see
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US05/38646 | 10/25/2005 | WO | 00 | 4/14/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60622015 | Oct 2004 | US |
